A Phase 1 Single Dose and Multiple Ascending Dose Study to Assess the Relative Bioavailability, Food Effect, Safety, Tolerability and Pharmacokinetics of SYT-510 in Healthy Participants

Phase 1 Completed 28 enrolled Synendos Therapeutics AG

RandomizedCrossoverOpen-labelTreatment

Summary

Part 1 aims to investigate the relative bioavailability of a new formulation and to assess potential food effects following oral administration of SYT-510. Part 1 will then guide dosing in Part 2, a multiple dose study which aims to assess safety, tolerability and pharmacokinetic of multiple SYT-510 administrations.

Timeline

Start: 2024-11-04
Primary completion: 2025-05-17
Completion: 2025-05-23

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SYT-510	Unknown	—	Oral

Indications

No indication recorded.